Lixte Biotechnology

56 articles with Lixte Biotechnology

• LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

  6/21/2022

  LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors.

• LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

  6/15/2022

  LIXTE Biotechnology Holdings, Inc.   (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Professor René Bernards to its Board of Directors.

• LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations

  4/12/2022

  LIXTE Biotechnology Holdings, Inc announces that Professor René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100, at the Annual Meeting of American Association for Cancer Research.

• LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

  4/12/2022

  LIXTE Biotechnology Holdings, Inc., a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced that it has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE’s common stock, at a purchase price of $2.00 per share, in a registered direct offering.

• Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy

  3/22/2022

  LIXTE Biotechnology Holdings, Inc., notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of SGO, that a subset of patients with OCCC treated with immune checkpoint inhibitors lived significantly longer than most patients with the same disease treated with the same regimens.

• LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference

  3/16/2022

  LIXTE Biotechnology Holdings, Inc. will present at the MedInvest Pharmaceutical and Biotechnology Investor Conference to be held March 28 - April 1, 2022.

• Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

  1/5/2022

  Lixte Biotechnology Holdings, announced today that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy.

• 

  Clinical Catch-Up: November 22-26

  11/29/2021

  Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.

• LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS

  11/22/2021

  Lixte Biotechnology Holdings, Inc . announced that the National Cancer Institute (NCI) has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated.

• LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY

  8/3/2021

  Lixte Biotechnology Holdings, Inc. announced that its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer.

• LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

  7/22/2021

  Lixte Biotechnology Holdings, Inc commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A (PP2A) with LB-100 combined with the experimental drug, vosoritide (BioMarin), was even more effective than vosorotide alone in stimulating bone length and cartilage area.

• Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

  7/13/2021

  Lixte Biotechnology Holdings, Inc . noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer Biology program, was selected for the second time to receive the National Latino Leader Award and a scholarship to present virtually studies of LB-100 in triple negative breast cancer (TNBC) at the 2021 Society of Advancing Chicanos/Hispanics and Native Americans in the Sciences Conference.

• Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

  4/13/2021

  Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the appointment of Gil N Schwartzberg to its Board of Directors. Mr. Schwartzberg is filling a vacancy created by the resignation of Winson (Sze Chun) Ho, M.D.

• Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24

  3/17/2021

  More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity

• Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

  3/2/2021

  Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $4.19 million of common stock.

• Lixte Biotechnology Announces $4.19 Million Registered Direct Offering

  3/1/2021

  Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of 1,133,102 shares of Lixte’s common stock, at a purchase price of $3.70 per share, in a registered direct offering.

• Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer

  1/19/2021

  Lixte Biotechnology Holdings, Inc . (NASDAQ: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced an agreement on a Phase 1b clinical trial with City of Hope , a world-renowned independent cancer research and treatment center. The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for un

• WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)

  11/30/2020

  WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, announced the closing of the follow-on offering for its client Lixte Biotechnology Holdings, Inc. 1,200,000 units consisting of one share of common stock and one warrant were sold for a total of $5,700,000 in gross proceeds.

• 

  Biopharma Money on the Move: October 7-14

  10/15/2020

  Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

• Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer

  7/21/2020

  Lixte Biotechnology Holdings, Inc. ( OTCQB: LIXT ) today announced the appointment of Dr. James Miser as its Chief Medical Officer commencing August 1, 2020. Dr. John S. Kovach, founder and CEO of Lixte, commented, “We are thrilled to welcome Jim Miser to our management team as we expand proof-of-principle clinical trials of our novel lead compound, LB-100. Dr. Miser is an expert in the design and monitoring of studies of new investigati